Lecture Details - Overview
Optimizing Adjuvant Endocrine Therapy: Where Do We Stand in 2008?
Release Date: August 22, 2008|
Expiration Date: September 10, 2009
Jul 23, 2008, Koloa, HI
Lecture Overview
This activity will update physicians on the latest clinical data concerning the selection of adjuvant endocrine therapy regimens for pre- and post-menopausal patients with hormone receptor-positive early-stage breast cancer. This educational activity is directed toward medical, radiation, and surgical oncologists with an interest in the treatment of breast cancer. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity. Fellows, oncology nurses, oncology physician assistants, and pharmacists who are interested in the treatment of breast cancer are also invited to participate. At the conclusion of this activity, you should be able to:• Assess the ongoing risk of recurrence for patients with hormone receptor–positive breast cancer and the implications for adjuvant endocrine therapy strategies
• Compare the efficacy/safety of up-front aromatase inhibitor therapy to that of tamoxifen/aromatase inhibitor switching or sequencing strategies in the adjuvant setting
• Discuss the effects of polymorphisms in CYP2D6 or other metabolic enzymes and of drugs that inhibit CYP2D6 activity on tamoxifen metabolism and their implications for treatment decisions for patients with hormone receptor–positive breast cancer
• Discuss the rationale for extended adjuvant endocrine therapy and recent data from trials investigating different durations of therapy
Instructions for Participation
- Read the following information before beginning the educational activity.
- Complete the CME pre-test.
- View and study all Flash video presentations.
- Complete the CME test.
- Answer the evaluation questions.
- CME credit will be granted for online participation only.
You will be asked to login
or create an account.